My airport driver needs my flight number. Who needs the rest of the email?
An airport pickup shows how much personal data an AI booking service really needs, and what to ask before sharing a family itinerary.


A JOURNAL OF PERSPECTIVE
Progress gives us possibilities.
Perspective helps us choose.
Notes on health, money and the future—exploring what is changing, what we may have overlooked, and what it could mean for our lives.
TURN THE PERSPECTIVE
If we can detect more, what should we do differently?Fresh questions. Considered perspectives.
An airport pickup shows how much personal data an AI booking service really needs, and what to ask before sharing a family itinerary.
The firm is licensed. How do you check whether the person who sent the offer represents it?
What melanoma patients and investors can each learn from the same trial.
A pharmacy reading, a kaya toast excuse and one question to ask before you leave.
Three siblings split Mum’s clinic bill. What about the half-day’s pay her daughter gave up to take her?
A parent can keep the value of an investment private and still tell the family which broker to call.
Two parents can have the same EPF balance and very different room to give. What i-Legasi changes for EPF, for families and for your own retirement.
The reasoning behind Solve Everything, two real research examples, and what I take from a hopeful—but uncertain—medical future.
A fake interview was one entry point. My takeaway: security should allow for human mistakes and limit how far one breach can spread.
Humanoid robots invite us to imagine a future with more independence, better support—and perhaps someone else doing the washing-up.
Manufactured organs could expand our options. What separates a scientific breakthrough from a treatment a particular family can actually access?
Google Cloud revenue doubled, yet Alphabet shares fell. A closer look at growth, expectations and the cash needed to build AI’s future.
ER-100 brings new hope for restoring function. How should we think about longer lives when healthy years and care needs remain uncertain?
MediAsas invites a better comparison: what costs would a plan carry, what would our household retain, and could we sustain both through a difficult year?
A legacy needs a workable handover as well as valuable assets. Who could access cash, with what authority, and when?
AlphaGenome Atlas offers more promising research clues. My view on separating faster discovery from better outcomes—and asking who will be ready to benefit.
Earlier cancer detection offers a hopeful possibility: more time to understand, prepare and explore our options. What would help us make that time count?
A NOTE FROM THE EDITOR
“I’m interested in a brighter future.
And the questions that help us prepare for it.”
Hope and preparation belong in the same conversation. This journal makes room for both.
A little more about Risk Steward ↗Health & Longevity
Could AI help us overcome diseases that still shorten lives today? In Solve Everything: Achieving Abundance by 2035, Peter Diamandis and Alexander Wissner-Gross lay out an ambitious vision of that future. Their timeline is a projection, not a medical finding. [1]
Peter Diamandis is a physician and entrepreneur who founded XPRIZE, an organisation that uses competitions to tackle major challenges. Alexander (Alex) Wissner-Gross is a physicist, computer scientist and entrepreneur working in AI. [8] [9]

Their argument starts with a bottleneck: there are only so many experts, and research takes time. They believe increasingly capable, cheaper AI, connected to automated laboratories, could allow far more ideas to be developed and tested. [2]
For medicine, they imagine computer models of cells and organs that let researchers explore disease and possible treatments before testing them in people. They also envisage earlier prevention and organs made on demand. These are goals in their proposed future, not capabilities already available for every patient. [1]
In everyday terms, imagine being able to check thousands of possible solutions before choosing which ones to investigate in a laboratory. That could make the search more productive. The computer’s answer would still need to survive real-world testing.
AlphaFold 3, published in 2024, predicts how proteins and other biological molecules fit together. That can help researchers understand interactions relevant to drug development. It predicts molecular structures; it does not demonstrate that a medicine cures a person. [3]
Another example is rentosertib, developed using AI to help identify a drug target and design a candidate for a serious lung-scarring disease. A 2025 study tested it in 71 patients in a randomized phase 2a trial, with safety as the main measure. That is meaningful progress into human testing, not proof of a cure. [4]
These examples help explain the optimism. They do not establish that most diseases will be cured by 2035. Safe, effective treatment and practical access remain separate hurdles; clinical testing and regulatory review still matter. [5]
I am hopeful about the direction, while keeping an open mind about the timetable. More illnesses becoming treatable could mean more ordinary days with family, more independence and more choices.
My response is to keep looking after today’s health, continue recommended care, and review our plans as the evidence develops. Even successful treatment can involve time away from work, with household bills continuing during recovery.
For those finding it difficult to build savings, affordable insurance can transfer some covered financial risks to an insurer while savings grow. Medical cover can help with eligible bills; a critical illness cash benefit can help with living costs when policy conditions are met. [6] [7] Start with existing support and what the budget can sustain. Future treatments are not automatically covered.
I welcome a future with better medicine. Preparing for it means protecting our choices today, without making our plans depend on a promised breakthrough date.
[1] Solve Everything: Achieving Abundance by 2035—authors’ vision and qualifications
[2] Alex Wissner-Gross: Explanation of the central argument, 14 February 2026
[3] Abramson et al., Nature (2024): AlphaFold 3 and biomolecular interactions
[4] Nature Medicine (2025): Randomized phase 2a rentosertib trial
[5] FDA: Drug development and review
[6] MyCoverage: Budget and medical insurance conditions
[7] EPF (KWSP): Types of insurance and critical illness cash benefits
[8] XPRIZE: Peter Diamandis—background
[9] Alexander Wissner-Gross: Background and research interests
Reviewed: 6 November 2026. General education and personal commentary. Research examples are distinct from the authors’ projections. Treatment and insurance eligibility depend on the person and applicable terms.
A QUESTION TO CARRY FORWARD
Original article ↗